Neuropathic Pain and Sickle Cell Disease: a Review of Pharmacologic Management

Orhurhu, Mariam Salisu; Chu, Robert; Claus, Lauren; Roberts, J; Salisu, Bisi; Urits, Ivan; Orhurhu, Ejovwoke; Viswanath, Omar; Kaye, Alan D.; Kaye, Aaron J.; Orhurhu, Vwaire

doi:10.1007/s11916-020-00885-5

Cited by 18 publications

(21 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Targeted medication regimens for NP have been reported in the SCD literature . First‐line treatment options for NP in SCD include anticonvulsants (gabapentin and pregabalin) and antidepressants, specifically tricyclic antidepressants (amitriptyline) and selective serotonin‐norepinephrine reuptake inhibitors (venlafaxine and duloxetine) 14 . These medications are also general first‐line treatment options for NP in conditions other than SCD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of neuropathic pain in adolescents with sickle cell disease: A single‐center experience

Cregan

Puri

Kang

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background Neuropathic pain (NP) has been previously explored in adolescents with sickle cell disease (SCD). This study aims to describe the prevalence of NP in adolescents with SCD at a single institution and to explore associated risk factors. Procedure We used the painDETECT questionnaire, one of the few pain phenotyping questionnaires validated for adolescents. We also evaluated the relationships between painDETECT scores and frequency of acute care visits and admissions for pain in the previous 12 months, and age, respectively. Patients 12–18 years old were surveyed from June to July 2019. A retrospective approach was used to answer the remaining research questions. Results Eighty‐one and seven surveys were completed in the outpatient and inpatient settings, respectively. PainDETECT scores suggestive of NP were more prevalent in inpatient surveys than in outpatient surveys. The difference between the mean painDETECT scores of each group was significant when using a general linear mixed model. Most inpatients surveyed had ≥3 pain events in the previous 12 months. Further, older age and increased number of pain events in the previous 12 months were independently associated with higher painDETECT scores. Conclusions Overall, in our opinion, NP is not being evaluated for and treated sufficiently in pediatric SCD, especially in the setting of inpatient acute vaso‐occlusive crisis. Age and number of acute pain events/admissions in the previous 12 months can be used to identify patients likely to be at risk for NP. It is important to continue to identify NP and develop NP‐targeting treatment plans.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Age and female gender are also risk factors for NP in the general population. Despite recent evidence showing that NP is a substantial component of sickle cell pain, its pathophysiology in SCD and its targeted treatment are not completely understood 3,4,10,11,13–15 …”

Section: Introductionmentioning

confidence: 99%

Prevalence of neuropathic pain in adolescents with sickle cell disease: A single‐center experience

Cregan

Puri

Kang

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…This lack of negative ratings was not only limited to interventional radiologists, but also spanned other medical specialties. Several studies corroborated this finding by noting that the average physician rating across all specialties was consistently very positive [11][12][13][14][15][16]. Sparse negative ratings could also be attributed to legal restrictions on entering negative feedback in some countries, such as Switzerland.…”

Section: Iq Issuesmentioning

confidence: 90%

“…Dimension Issues [9][10][11][12][13][14][15][16] Accuracy and objectivity Ratings were either positive or extremely positive, with a notable absence of negative ratings.…”

Section: Citationsmentioning

confidence: 99%

Data Quality Issues With Physician-Rating Websites: Systematic Review (Preprint)

Mulgund¹,

Sharman²,

Anand³

et al. 2019

Preprint

View full text Add to dashboard Cite

BACKGROUND Online physician rating websites have witnessed a steep rise in prominence over the years and exert considerable influence on high-stake patient decisions. However, the quality of these decisions depends on the quality of data collected by these systems. Hence, there is a need to understand the various data quality issues that exist in such websites. OBJECTIVE The purpose of this systemic review is to collect the data quality issues discussed in previous studies and classify them based on the data quality framework put forward by Wang et al. This review summarizes the findings and provides an in-depth discussion of various categories of data quality issues and their implications on the users of physician rating websites. METHODS We performed a systematic literature search in ACM Digital Library, EBSCO, Springer, PubMed, and Google Scholar. We identified any quantitative, qualitative and mixed-method paper that investigated data quality issues in physician rating websites. Over 192 articles were screened, and 33 were analyzed and summarized for this systematic review. RESULTS We identified 33 studies to collect 19 unique data quality issues that afflict physician rating sites. We classify these issues into 4 categories: Intrinsic, Contextual, Accessible and Representational. 58% (19/33) papers reported the presence of Intrinsic data quality errors, 48% (16/33) highlighted Contextual data quality issues. A small yet considerable number of studies (10/33) discussed issues of Representational & Accessibility data quality. More than half of the papers discuss multiple categories of data quality issues. CONCLUSIONS The results of this review demonstrate the presence of a range of data quality issues. While Intrinsic and Contextual factors have been well researched, Accessibility and Representational issues warrant more attention from researchers as well as practitioners. Notably, the Representational factors such as the impact of inline advertisements, positioning of positive reviews, which are usually deliberate and an artifact of the business or revenue model of the PRWs warrant more emphasis.

show abstract

“…The prevalence of neuropathic pain in the U.S.A. is similar to that in other industrialized countries; the prevalence in Canada and the UK was reported to be 7.7% [ 28 ] and 8% [ 26 ], respectively. Neuropathic pain is often associated with a specific condition, such as diabetes, traumatic brachial plexus injury, bone metastases, sickle cell disease, and advanced cancer; the prevalence of neuropathic pain for these diseases has been reported to be 50%, 56%, 25.8%, 20–25% and 30.6%, respectively [ 29 , 30 , 31 , 32 , 33 ]. It is important that clinicians consider the existence of neuropathic pain characteristics when treating patients so as to optimize patient care and the management of symptoms.…”

Section: Epidemiology Of Neuropathic Painmentioning

confidence: 99%

Glycosides for Peripheral Neuropathic Pain: A Potential Medicinal Components

Tian

Liu

et al. 2021

Molecules

View full text Add to dashboard Cite

Neuropathic pain is a refractory disease that occurs across the world and pharmacotherapy has limited efficacy and/or safety. This disease imposes a significant burden on both the somatic and mental health of patients; indeed, some patients have referred to neuropathic pain as being ‘worse than death’. The pharmacological agents that are used to treat neuropathic pain at present can produce mild effects in certain patients, and induce many adverse reactions, such as sedation, dizziness, vomiting, and peripheral oedema. Therefore, there is an urgent need to discover novel drugs that are safer and more effective. Natural compounds from medical plants have become potential sources of analgesics, and evidence has shown that glycosides alleviated neuropathic pain via regulating oxidative stress, transcriptional regulation, ion channels, membrane receptors and so on. In this review, we summarize the epidemiology of neuropathic pain and the existing therapeutic drugs used for disease prevention and treatment. We also demonstrate how glycosides exhibit an antinociceptive effect on neuropathic pain in laboratory research and describe the antinociceptive mechanisms involved to facilitate the discovery of new drugs to improve the quality of life of patients experiencing neuropathic pain.

show abstract

Neuropathic Pain and Sickle Cell Disease: a Review of Pharmacologic Management

Cited by 18 publications

References 136 publications

Prevalence of neuropathic pain in adolescents with sickle cell disease: A single‐center experience

Prevalence of neuropathic pain in adolescents with sickle cell disease: A single‐center experience

Data Quality Issues With Physician-Rating Websites: Systematic Review (Preprint)

Glycosides for Peripheral Neuropathic Pain: A Potential Medicinal Components

Contact Info

Product

Resources

About